Olmesartan reduces inflammatory biomarkers in patients with stable coronary artery disease undergoing percutaneous coronary intervention: Results from the OLIVUS trial

Heart and Vessels

Volumn 29, Issue 2, 2014, Pages 178-185

  Miyoshi, Toru ^a   Hirohata, Atsushi ^b   Usui, Shinichi ^c   Yamamoto, Keizo ^b   Murakami, Takashi ^d   Komatsubara, Issei ^e   Kusachi, Shozo ^c   Ohe, Tohru ^b   Nakamura, Kazufumi ^a   Ito, Hiroshi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b THE SAKAKIBARA HEART INSTITUTE OF OKAYAMA   (Japan)

^c OKAYAMA UNIVERSITY   (Japan)

^d Okayama Heart Clinic   (Japan)

^e Tsuyama Central Hospital   (Japan)

Author keywords

Angiotensin II receptor blocker; Coronary artery disease; Inflammation; Olmesartan

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLMESARTAN; TRIACYLGLYCEROL; ADIPOQ PROTEIN, HUMAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIINFLAMMATORY AGENT; AUTACOID; IMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

AGED; ARTICLE; ATHEROMA; BLOOD PRESSURE REGULATION; BLOOD SAMPLING; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PERCUTANEOUS CORONARY INTERVENTION; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; STABLE ANGINA PECTORIS; SYSTOLIC BLOOD PRESSURE; ANGINA, STABLE; ATHEROSCLEROTIC PLAQUE; BLOOD; CORONARY BLOOD VESSEL; DOWN REGULATION; DRUG EFFECTS; ENDOSCOPIC ECHOGRAPHY; JAPAN; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; TIME; TREATMENT OUTCOME; ULTRASTRUCTURE;

ADIPONECTIN; AGED; ANGINA, STABLE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTI-INFLAMMATORY AGENTS; BIOMARKERS; C-REACTIVE PROTEIN; CORONARY ARTERY DISEASE; CORONARY VESSELS; DISEASE PROGRESSION; DOWN-REGULATION; FEMALE; HUMANS; IMIDAZOLES; INFLAMMATION MEDIATORS; JAPAN; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLAQUE, ATHEROSCLEROTIC; PROSPECTIVE STUDIES; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84897020719     PISSN: 09108327     EISSN: 16152573     Source Type: Journal    
DOI: 10.1007/s00380-013-0343-0     Document Type: Article

References (30)

1. Saito M, Ishimitsu T, Minami J, Ono H, Ohrui M, Matsuoka H (2003) Relations of plasma high-sensitivity C-reactive protein to traditional cardiovascular risk factors. Atherosclerosis 167(1):73-79 (Pubitemid 36255637)
2. Ross R (1999) Atherosclerosis-an inflammatory disease. N Engl J Med 340(2):115-126
3. Ridker PM (2003) Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107(3):363-369
4. Kotani K, Yamada T, Miyamoto M, Kario K, Ishibashi S, Taniguchi N (2012) The correlation between the cardio-ankle vascular index (CAVI) and serum amyloid A in asymptomatic Japanese subjects. Heart Vessels 27(5):499-504. doi:10.1007/s00380-011-0182-9
5. Divchev D, Grothusen C, Luchtefeld M, Thoenes M, Onono F, Koch R, Drexler H, Schieffer B (2008) Impact of a combined treatment of angiotensin II type 1 receptor blockade and 3-hydroxy-3-methyl-glutaryl-CoA-reductase inhibition on secretory phospholipase A2-type IIA and low density lipoprotein oxidation in patients with coronary artery disease. Eur Heart J 29(16):1956-1965
6. Fujiwara W, Izawa H, Ukai G, Yokoi H, Mukaide D, Kinoshita K, Morimoto SI, Ishii J, Ozaki Y, Nomura M (2012) Low dose of hydrochlorothiazide, in combination with angiotensin receptor blocker, reduces blood pressure effectively without adverse effect on glucose and lipid profiles. Heart Vessels. doi:10.1007/s00380-012-0246-5
7. Naya M, Tsukamoto T, Morita K, Katoh C, Furumoto T, Fujii S, Tamaki N, Tsutsui H (2007) Olmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients. J Am Coll Cardiol 50(12):1144-1149 (Pubitemid 47375012)
8. Miyoshi T, Doi M, Hirohata S, Kamikawa S, Usui S, Ogawa H, Sakane K, Izumi R, Ninomiya Y, Kusachi S (2011) Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients. Heart Vessels 26(4):408-413
9. Fliser D, Buchholz K, Haller H (2004) Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 110(9):1103-1107 (Pubitemid 39319009)
10. Hirohata A, Yamamoto K, Miyoshi T, Hatanaka K, Hirohata S, Yamawaki H, Komatsubara I, Murakami M, Hirose E, Sato S, Ohkawa K, Ishizawa M, Yamaji H, Kawamura H, Kusachi S, Murakami T, Hina K, Ohe T (2010) Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis: evaluation by IntraVascular UltraSound) trial. J Am Coll Cardiol 55(10):976-982
11. Hirohata A, Yamamoto K, Miyoshi T, Hatanaka K, Hirohata S, Yamawaki H, Komatsubara I, Hirose E, Kobayashi Y, Ohkawa K, Ohara M, Takafuji H, Sano F, Toyama Y, Kusachi S, Ohe T, Ito H (2012) Four-year clinical outcomes of the OLIVUS-Ex (impact of Olmesartan on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) extension trial. Atherosclerosis 220(1):134-138
12. Nakamura M, Yock PG, Bonneau HN, Kitamura K, Aizawa T, Tamai H, Fitzgerald PJ, Honda Y (2001) Impact of peri-stent remodeling on restenosis: a volumetric intravascular ultrasound study. Circulation 103(17):2130-2132 (Pubitemid 32458320)
13. (2008) Standards of medical care in diabetes - 2008. Diabetes Care 31(Suppl 1):S12-S54
14. Miyoshi T, Onoue G, Hirohata A, Hirohata S, Usui S, Hina K, Kawamura H, Doi M, Kusano KF, Kusachi S, Ninomiya Y (2010) Serum adipocyte fatty acid-binding protein is independently associated with coronary atherosclerotic burden measured by intravascular ultrasound. Atherosclerosis 211(1):164-169
15. Lorenzen JM, Neunhoffer H, David S, Kielstein JT, Haller H, Fliser D (2010) Angiotensin II receptor blocker and statins lower elevated levels of osteopontin in essential hypertension - results from the EUTOPIA trial. Atherosclerosis 209(1):184-188
16. Brasier AR, Recinos A 3rd, Eledrisi MS (2002) Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 22(8):1257-1266 (Pubitemid 34875734)
17. Libby P (2002) Inflammation in atherosclerosis. Nature 420(6917):868-874
18. Mervaala EM, Muller DN, Park JK, Schmidt F, Lohn M, Breu V, Dragun D, Ganten D, Haller H, Luft FC (1999) Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. Hypertension 33(1 Pt 2):389-395 (Pubitemid 29065690)
19. Ohtani K, Egashira K, Ihara Y, Nakano K, Funakoshi K, Zhao G, Sata M, Sunagawa K (2006) Angiotensin II type 1 receptor blockade attenuates in-stent restenosis by inhibiting inflammation and progenitor cells. Hypertension 48(4):664-670 (Pubitemid 44843870)
20. Takai S, Jin D, Sakaguchi M, Muramatsu M, Miyazaki M (2005) The regressive effect of an angiotensin II receptor blocker on formed fatty streaks in monkeys fed a high-cholesterol diet. J Hypertens 23(10):1879-1886 (Pubitemid 41830428)
21. Sasaki T, Kuzuya M, Nakamura K, Cheng XW, Hayashi T, Song H, Hu L, Okumura K, Murohara T, Iguchi A, Sato K (2010) AT1 blockade attenuates atherosclerotic plaque destabilization accompanied by the suppression of cathepsin S activity in apoE-deficient mice. Atherosclerosis 210(2):430-437
22. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, Orazem J, Magorien RD, O'Shaughnessy C, Ganz P (2005) Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352(1):29-38 (Pubitemid 40075678)
23. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E (2005) C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352(1):20-28 (Pubitemid 40075677)
24. Tsutamoto T, Nishiyama K, Yamaji M, Kawahara C, Fujii M, Yamamoto T, Horie M (2010) Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension. Hypertens Res 33(2):118-122
25. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM (2004) Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 43(5):970-976 (Pubitemid 38579900)
26. Fujimoto S, Satoh M, Horike H, Hatta H, Haruna Y, Kobayashi S, Namikoshi T, Arakawa S, Tomita N, Kashihara N (2008) Olmesartan ameliorates progressive glomerular injury in subtotal nephrectomized rats through suppression of superoxide production. Hypertens Res 31(2):305-313 (Pubitemid 351461111)
27. Yamashita C, Hayashi T, Mori T, Tazawa N, Kwak CJ, Nakano D, Sohmiya K, Okada Y, Kitaura Y, Matsumura Y (2007) Angiotensin II receptor blocker reduces oxidative stress and attenuates hypoxia-induced left ventricular remodeling in apolipoprotein E-knockout mice. Hypertens Res 30(12):1219-1230 (Pubitemid 351176420)
28. Kurata A, Nishizawa H, Kihara S, Maeda N, Sonoda M, Okada T, Ohashi K, Hibuse T, Fujita K, Yasui A, Hiuge A, Kumada M, Kuriyama H, Shimomura I, Funahashi T (2006) Blockade of angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int 70(10):1717-1724 (Pubitemid 44684802)
29. Takayama T, Hiro T, Yamagishi M, Daida H, Hirayama A, Saito S, Yamaguchi T, Matsuzaki M (2009) Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Circ J 73(11):2110-2117
30. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM (2006) Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295(13):1556-1565